
BackgroundSudden cardiac death (SCD) from malignant ventricular arrhythmias (VA) remains a major unresolved challenge in dilated cardiomyopathy (DCM). The traditional left ventricular ejection fraction (LVEF)-based strategy misses a substantial proportion of at-risk patients, yet no universally accepted alternative has been established.ObjectivesThis review aims to synthesize current evidence on the molecular mechanisms of VA in DCM and to evaluate the utility of emerging multidimensional risk stratification tools—incorporating cardiac magnetic resonance (CMR), genetic testing, and clinical parameters—in refining SCD prediction and guiding implantable cardioverter-defibrillator (ICD) decisions.MethodsWe searched PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2000 to May 2026 using combinations of terms including “dilated cardiomyopathy,” “ventricular arrhythmia,” “sudden cardiac death,” “calcium handling,” “RyR2,” “SERCA2a,” “LMNA,” “FLNC,” “RBM20,” “cardiac magnetic resonance,” “late gadolinium enhancement,” and “risk stratification.” We focused on calcium handling remodeling, genotype-specific arrhythmic susceptibility, and myocardial fibrosis as the structural substrate for VA, and critically appraised the evidence for CMR-based quantification and genotype-guided risk assessment.Key findingsCalcium dysregulation (RyR2-mediated sarcoplasmic reticulum Ca2+ leak, SERCA2a dysfunction, and L-type calcium channel overactivation) is a core arrhythmic driver in DCM. Genotypes including LMNA, FLNC, RBM20, and desmosomal variants carry high VA risk independent of LVEF. Late gadolinium enhancement (LGE) on CMR—particularly ≥7.2% of left ventricular mass—substantially improves SCD prediction over LVEF alone. A stepwise CMR-based risk model and a bedside clinical prediction tool (incorporating age, LVEF, glucose, potassium, and eGFR) are now available for practical risk stratification.ConclusionsA multidimensional approach integrating CMR quantification, genotype, and clinical parameters offers superior SCD risk stratification compared with LVEF alone. This framework can inform ICD decision-making and represents a practical path toward precision management of VA in DCM.
BackgroundPatients after Fontan operation are at risk for multisystemic complications. Chronically elevated central venous pressure and reduced cardiac output may promote intestinal congestion and hypoperfusion, potentially leading to intestinal barrier dysfunction, microbial translocation and systemic inflammation.ObjectivesTo investigate biomarkers of intestinal barrier dysfunction and systemic inflammation in adult patients after Fontan operation without protein losing enteropathy (PLE).MethodsIn this single-center, prospective study adult patients after Fontan operation without PLE and age- and sex-matched healthy controls were enrolled. Intestinal barrier related biomarkers included lipopolysaccharide binding protein (LBP), a marker of endotoxin exposure and host acute phase response, and intestinal fatty-acid binding protein (I-FABP), a marker of enterocyte injury. Systemic inflammation was evaluated using interleukin-6, interleukin-1β, tumor necrosis factor-α, soluble CD14 and C-reactive protein.ResultsTwenty-six patients after Fontan operation and thirteen healthy controls were included. There were no differences in age (27 ± 6 vs. 28 ± 4 years, p = 0.474) or gender (12 (46%) vs. 6 (46%) women, p = 1.000). Of intestinal barrier dysfunction biomarkers, LBP levels were significantly higher in patients than in healthy controls (median 19.0 (6.9) vs. 12.6 (1.3) ng/mL, p = 0.038), whereas I-FABP levels were similar (median 1.7 (1.0) vs. 1.5 (0.7) ng/mL, p = 0.627). All inflammatory biomarkers were significantly elevated in patients after Fontan operation.ConclusionsAdult patients after Fontan operation without PLE showed higher LBP and biomarkers of systemic inflammation, but similar I-FABP, compared to healthy controls. This pattern is consistent with increased endotoxin exposure and low-grade systemic inflammation without evidence of overt enterocyte injury in these complex patients.
ObjectiveTo systematically evaluate the association between remnant cholesterol (RC) and hypertension and examine how outcome definition, exposure scale, and adjustment for baseline blood pressure affect pooled estimates.MethodsThis review was registered in INPLASY (INPLASY202670098). PubMed, Embase, Web of Science Core Collection, and the Cochrane Library were searched through October 12, 2026. Reference lists of included studies and relevant systematic reviews and available supplementary materials were also examined. Observational studies evaluating RC and hypertension were included, with evidence organized separately for incident, prevalent, and maternal outcomes. Compatible HRs or ORs were pooled using inverse-variance random-effects models, with each potentially overlapping source population contributing one estimate per analysis. Uncertainty was assessed using modified Hartung–Knapp intervals, 95% prediction intervals when at least three independent sources were available, source-replacement analyses, and exploratory subgroup analyses. An exploratory two-stage linear dose–response analysis was also performed.ResultsTwenty-three study reports were included. For the highest versus lowest baseline RC categories, the pooled HR for incident hypertension from five independent source populations was 1.40 (95% CI: 1.05–1.85; I2 = 97.5%), and the pooled OR for prevalent hypertension from three source populations was 1.60 (95% CI: 1.17–2.19; I2 = 95.0%). The corresponding modified Hartung–Knapp intervals were 0.93–2.09 and 0.80–3.19. Pooled HRs were 1.92 and 1.17 in models without and with baseline blood pressure adjustment, respectively, although populations and other covariates also differed between groups. Four independent source populations contributed to the two-stage linear dose–response meta-analysis. The pooled HR for incident hypertension per 1 mmol/L higher RC was 1.32 (95% CI: 1.18–1.47; I2 = 40.9%), with a modified Hartung–Knapp interval of 1.08–1.61 and a 95% prediction interval of 0.88–1.98. After replacing the CHARLS report, the pooled HR was 1.27 (95% CI: 1.14–1.40). A pooled nonlinear association was not evaluated. The pooled OR for preeclampsia was 1.83 (95% CI: 1.47–2.29), based on only two sources, with a modified interval of 0.44–7.65.ConclusionsHigher RC was positively associated with incident and prevalent hypertension, and the exploratory dose–response analysis suggested a positive linear trend. High heterogeneity, few independent sources, differences in adjustment strategies, and approximations in dose–response reconstruction limit assessment of association magnitude and applicability across populations. Causality and clinical utility require further investigation.Systematic Review Registrationhttps://doi.org/10.37766/inplasy2026.7.0098, identifier INPLASY202670098.
BackgroundAdvanced age has historically been considered a relative contraindication to extracorporeal membrane oxygenation (ECMO) due to poor reported outcomes. However, contemporary guidelines advocate for comprehensive geriatric assessment over chronological age alone. Nevertheless, nursing literature on standardized care for ultra-elderly patients (≥90 years) requiring ECMO support remains scarce.Case presentationA 95-year-old woman presented with acute inferior ST-segment elevation myocardial infarction (STEMI) complicated by refractory cardiogenic shock (Killip class IV) and third-degree atrioventricular block. Given her extreme age, the family initially hesitated to consent to ECMO, prompting the placement of an intra-aortic balloon pump (IABP) as a bridge while emergency percutaneous coronary intervention (PCI) commenced. Following renewed consent, VA-ECMO was established via the right femoral artery and vein, running in parallel with the IABP to ensure hemodynamic stability during the procedure. The patient was successfully weaned from ECMO after 13 h of support and decannulated. The IABP and tracheal tube were successfully removed the following day. The nursing care was retrospectively reviewed and organized into four domains, informed by the Iowa Model of Evidence-Based Practice and Orem's Self-Care Deficit Theory.OutcomesOn admission, the patient already had severe coagulopathy (PT 17.6 s, INR 1.44, PT activity 57.00%, TT >240.0 s, fibrinogen 1.87 g/L, APTT >180.0 s, D-dimer 4.38 mg/L, FDP 18.46 μg/mL), anemia (Hb 60 g/L), and hypoalbuminemia (23.9 g/L). During hospitalization, she developed right lower limb hypoperfusion (unmeasurable toe oxygen saturation, right groin ecchymosis) despite the use of a distal perfusion catheter, and a nosocomial worsening of a pre-existing pneumonia on day 4. VA-ECMO support lasted 13 h 15 min with concomitant IABP; she was successfully weaned and discharged on day 6 at the family's request. Discharge diagnoses included a puncture-site hematoma and suspected ischemic changes of the right toes.ConclusionThis case documents real complications, including severe coagulopathy requiring transfusion, right lower limb hypoperfusion, right groin ecchymosis, and hospital-acquired pneumonia-together with a puncture-site hematoma and suspected toe gangrene recorded at discharge. These were managed without unplanned decannulation, major device-related infection, or pressure injury. It is presented as a hypothesis-generating, educational resource; causality cannot be inferred from a single case. The decision trajectory in this case—initial refusal of ECMO, IABP bridging, and family-initiated weaning—is itself instructive for ultra-elderly mechanical support. Multicenter prospective studies are warranted.